Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carfilzomib Multiple Myeloma Data Do New Onyx Parent Proud At ASH '09

This article was originally published in The Pink Sheet Daily

Executive Summary

When all else fails, call on carfilzomib: Phase II data support end-2010 NDA filing for next-generation Velcade.

You may also be interested in...



Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

Carfilzomib On Track For End-of-Year Submission After Surprising Top-line Phase II Results

Onyx's next-generation proteasome inhibitor shows a 24% response rate, 7.4 month durable response as a salvage therapy in multiple myeloma.

Related Content

Topics

UsernamePublicRestriction

Register

PS068945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel